Exhibit 10.1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE REPARE THERAPEUTICS INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO REPARE THERAPEUTICS INC. IF PUBLICLY DISCLOSED.
FOURTH AMENDMENTTO
COLLABORATION AND LICENSEAGREEMENT
This Fourth Amendment to Collaboration and License Agreement (this “Fourth Amendment”) is entered into as of May 16, 2023 (the “Fourth Amendment Effective Date”) by and between Repare Therapeutics Inc., a Canadian corporation with offices at 7210 Frederick-Banting, Suite 100, St. Laurent, Quebec, Canada H4S 2A1 (“Repare Inc.”) and Repare Therapeutics USA, Inc., a Delaware corporation with offices at 101 Main Street, Suite 1650, Cambridge, Massachusetts 02142 (“Repare USA” and, together with Repare Inc., “Repare”), on the one hand, and Bristol-Myers Squibb Company, a Delaware corporation with offices at 430 E. 29th Street, 14th Floor, New York, New York 10016 (“BMS”), on the other hand. BMS and Repare are each referred to herein by name or as a “Party”, or, collectively, as the “Parties.”
WHEREAS, Repare and BMS entered into that certain Collaboration and License Agreement as of May 26, 2020 (as amended, the “Agreement”);
WHEREAS, the [***] is an Existing Repare Campaign that has been designated a Primary Campaign;
WHEREAS, following Initial Screening for such Primary Campaign, Repare has identified certain Targets as showing promise for Synthetic Lethalityas Collaboration Targets with respect to such Primary Campaign;
WHEREAS, the Primary Target of the [***] Primary Campaign is [***] (“Target Y”) and the Secondary Target of the [***] Primary Campaign is [***] (“Target Z”); and
WHEREAS, the Parties wish to amend the Agreement to extend the Primary Target Review Period and the Additional Target Review Period of the Collaboration Targets for the [***] Primary Campaign;
NOW, THEREFORE, the Parties, intending to be legally bound, hereby agree as follows:
[Signature Page Follows]
IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Fourth Amendment to Collaboration and License Agreement to be executed by their respective duly authorized officers as of the Fourth Amendment Effective Date.
BRISTOL-MYERS SQUIBB COMPANY
By: /s/ Maria Engler
Name: Maria Engler
Title: Senior Director, Global Alliance
REPARE THERAPEUTICS INC.
By: /s/ Cameron Black
Name: Cameron Black
Title: EVP, Discovery
REPARE THERAPEUTICS INC.
By: /s/ Steve Forte
Name: Steve Forte
Title: EVP, CFO